Navigation Links
Isis Pharmaceuticals To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
Date:11/7/2012

CARLSBAD, Calif., Nov. 07, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 2:00 p.m. ET in New York, NY. 

A live audio webcast of the presentation and panel will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, in the United States and Europe following regulatory approval.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
2. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
4. Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
5. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
6. AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
7. Thom Rowland Joins Arbor Pharmaceuticals as Vice President of Commercial Operations
8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
9. Jazz Pharmaceuticals Announces Support for National Campaign Designed to Curb Prescription Drug Abuse
10. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
11. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)...  Nearly 30 million people in the ... diabetes. 1 However, nearly 40% of diabetes patients ... and significant glucose variability. 2 These patients are at ... If left untreated, hyperglycemia can lead to cardiovascular disease, ... 3 As part of Diabetes Awareness ...
(Date:12/6/2016)... Dec. 6, 2016  Arcturus Therapeutics, Inc. ("Arcturus" ... announced today that it entered into collaboration with ... for the treatment of NASH and other gastrointestinal ... platform LUNAR™ and UNA Oligomer chemistry. The financial ... long-standing commitment to and expertise in GI disorders, ...
(Date:12/6/2016)... 2016 Breast Pump Market size is estimated ... by Global Market Insights, Inc. Continue Reading ... ... , , ... women employment rates and rising consumer awareness regarding importance of breast feeding will ...
Breaking Medicine Technology:
(Date:12/6/2016)... CA (PRWEB) , ... December 06, 2016 , ... Individuals ... protective measures, such as drinking more water or limiting their exposure to the sun, ... California health and beauty group Beverly Hills Physicians (BHP) notes that, while preventive measures ...
(Date:12/6/2016)... ... December 06, 2016 , ... Mount Sinai Health System today ... of Neurosurgery, where clinicians can confer and order 3D models for their cases. ... basis with quick turnaround times. This resource will be the first of its ...
(Date:12/6/2016)... , ... December 06, 2016 , ... Why does the ... Proietto, MB BS, PhD, FRACP, includes a fresh look into the cause of obesity ... evidence-based strategy providing readers with the knowledge needed to lead a healthy life. Proietto ...
(Date:12/6/2016)... ... December 06, 2016 , ... The NALA, a boutique marketing agency, is ... Foundation (TBCF), a nonprofit 501(C)(3) organization providing financial and emotional support to families ... To assist TBCF, the NALA recently hosted a Thanksgiving food drive that resulted in ...
(Date:12/6/2016)... ... December 06, 2016 , ... The V ... announce its Not a Moment to Lose fundraising campaign. As the V Foundation’s ... to declaring victory over cancer. The campaign aims to raise $200 million by ...
Breaking Medicine News(10 mins):